Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 10.84% is 424% above its 5-year average of 2.07%, near the high end of its 5-year range (0.00%–10.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 68.17% above its 12-month average of 6.45%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.84%.
DEBT TO ASSETS RATIO
10.84%
DEBT TO ASSETS RATIO AVG TTM
6.45%
DEBT TO ASSETS RATIO AVG 3Y
3.23%
DEBT TO ASSETS RATIO AVG 5Y
2.07%
DEBT TO ASSETS RATIO AVG 10Y
1.23%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+68.17%
CURRENT VS 3Y AVG
+235.56%
CURRENT VS 5Y AVG
+424.14%
CURRENT VS 10Y AVG
+782.76%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 812 covered companies
CURRENT VS SECTOR MEDIAN
+11949.29%
vs the sector median at left
Co-Diagnostics, Inc.
Market Cap
$7.01M
Debt to Assets Ratio
10.84%
TTM Avg
6.45%
3Y Avg
3.23%
5Y Avg
2.07%
Market Cap
$6.99M
Debt to Assets Ratio
0.54%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.08M
Debt to Assets Ratio
0.17%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.08M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.90M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.31M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Co-Diagnostics, Inc. (CODX) | $7.01M | 10.84% | 6.45% | 3.23% | 2.07% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.99M | 0.54% | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.07M | 0.00% | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | 0.17% | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.08M | 0.02% | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $6.90M | 0.05% | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | 0.00% | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | 0.04% | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00% | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.34M | 0.00% | N/A | N/A | N/A |
Debt/Assets
10.8%
Debt/Equity
0.14
Current Ratio
1.81
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 10.84% |
| 2026-03-31 | 9.44% |
| 2025-12-31 | 5.00% |
| 2025-09-30 | 3.29% |
| 2025-06-30 | 3.67% |
| 2025-03-31 | 3.50% |
| 2024-12-31 | 3.36% |
| 2024-09-30 | 3.27% |
| 2024-06-30 | 3.20% |
| 2024-03-31 | 3.22% |
| 2023-12-31 | 3.14% |
| 2023-09-30 | 2.80% |
| 2023-06-30 | 2.86% |
| 2023-03-31 | 0.80% |
| 2022-12-31 | 0.28% |
| 2022-09-30 | 0.28% |
| 2022-06-30 | 0.30% |
| 2022-03-31 | 0.33% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 122.88% |
| 2018-09-30 | 68.88% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 734.94% |
| 2017-03-31 | 431.57% |
| 2016-12-31 | 261.92% |
| 2016-09-30 | 635.23% |
| 2015-12-31 | 272.70% |
